Techniques in Coloproctology

, Volume 14, Issue 2, pp 141–146 | Cite as

Risk factors predicting intra-abdominal desmoids in familial adenomatous polyposis: a single centre experience

  • A. Sinha
  • P. P. Tekkis
  • K. F. Neale
  • R. K. S. Phillips
  • S. K. ClarkEmail author
Original Article



Desmoids are myofibroblastic proliferations occurring in 15% of patients with familial adenomatous polyposis (FAP), 70% being intra-abdominal desmoids (IAD). Since the morbidity and mortality due to desmoids is almost entirely attributable to IAD, we aimed to identify specifically risk factors predicting IAD development in FAP.


We undertook a retrospective review of our institutional database. Multivariate analysis was performed, and hazard ratios (HR) calculated for variables including female gender, 3′ APC mutation, surgical intervention for FAP (colectomy with ileo-rectal anastomosis or restorative proctocolectomy), age at surgery and family history (FH) of desmoids.


Of the 558 patients analysed, 49 (9%) developed IAD; 22 (4%) diagnosed intra-operatively and 27 (5%) developing over a median post-operative period of 34 (7–120) months. 75% of IAD had developed before age 40. A 3′ APC mutation (HR 5.2, 95% CI 2.1–13.3, P = 0.001), positive FH (HR 2.5, 95% CI 1.4–4.6, P = 0.003) and female gender (HR 1.9, 95% CI 1.0–3.5, P = 0.04) were found to be predictive of IAD development. No significant difference in IAD risk was detected between the type of surgical intervention (P = 0.37) or age at surgery (P = 0.29).


Our analysis confirms 3′ APC mutation to be the most significant risk factor for IAD development. The independent association between positive FH and IAD risk suggests the existence of modifier genes, independent of the APC genotype–phenotype correlation. Few of these risk factors can be meaningfully modified. Delaying prophylactic surgery may be appropriate in female patients with a 3′ APC mutation and attenuated polyposis.


Desmoid tumour Familial adenomatous polyposis Risk factors 



The authors gratefully acknowledge Cancer Research UK for funding the St. Mark’s Hospital Polyposis Registry database and thank Muditha Samarasinghe, Jo Rawlings, Tina Isherwood and Pam Nye for maintaining the data.


  1. 1.
    Kinzler KW, Nilbert MC, Su LK et al (1991) Identification of FAP locus genes from chromosome 5q21. Science 253:661–664CrossRefPubMedGoogle Scholar
  2. 2.
    Bussey HJ (1987) Historical developments in familial polyposis coli. Semin Surg Oncol 3:67–70CrossRefPubMedGoogle Scholar
  3. 3.
    Vasen HF, Moslein G, Alonso A et al (2008) Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 57:704–713CrossRefPubMedGoogle Scholar
  4. 4.
    Aziz O, Athanasiou T, Fazio VW et al (2006) Meta-analysis of observational studies of ileorectal versus ileal pouch-anal anastamosis for familial adenomatous polyposis. Br J Surg 93:407–417CrossRefPubMedGoogle Scholar
  5. 5.
    Heiskanen I, Luostarinen T, Jarvinen HJ (2000) Impact of screening examinations on survival in familial adenomatous polyposis. Scand J Gastroenterol 35:1284–1287CrossRefPubMedGoogle Scholar
  6. 6.
    Bülow S, Bülow C, Nielsen TF et al (1995) Centralized registration, prophylactic examination, and treatment results in improved prognosis in familial adenomatous polyposis. Results from the Danish polyposis register. Scand J Gastroenterol 30:989–993CrossRefPubMedGoogle Scholar
  7. 7.
    Sturt NJ, Clark SK (2006) Current ideas in desmoid tumours. Fam Cancer 5:275–285CrossRefPubMedGoogle Scholar
  8. 8.
    Lofti AM, Dozois RR, Gordon H et al (1989) Mesenteric fibromatosis complicating familial adenomatous polyposis: predisposing factors and results of treatment. Int J Colorectal Dis 4:30–36CrossRefGoogle Scholar
  9. 9.
    Bertario L, Russo A, Sala P et al (2001) Genotype and phenotype factors as determinants of desmoid tumours in patients with familial adenomatous polyposis. Int J Cancer 95:102–107CrossRefPubMedGoogle Scholar
  10. 10.
    Heinimann K, Mullhaupt B, Weber W et al (1998) Phenotypic differences in familial adenomatous polyposis based on APC germline mutation status. Gut 43:675–679PubMedCrossRefGoogle Scholar
  11. 11.
    Bertario L, Presciuttini S, Sala P et al (1994) Causes of death and postsurgical survival in familial adenomatous polyposis: results from the Italian registry of familial polyposis writing committee. Semin Surg Oncol 10:225–234CrossRefPubMedGoogle Scholar
  12. 12.
    Arvanitis ML, Jagelman DG, Fazio VW et al (1990) Mortality in patients with familial adenomatous polyposis. Dis Colon Rectum 33:639–642CrossRefPubMedGoogle Scholar
  13. 13.
    Clark SK, Neale KF, Landgrebe JC et al (1999) Desmoid tumours complicating familial adenomatous polyposis. Br J Surg 86:1185–1189CrossRefPubMedGoogle Scholar
  14. 14.
    Church JM (1995) Desmoid tumours in patients with familial adenomatous polyposis. Semin Colon Rectal Surg 6:29–32Google Scholar
  15. 15.
    Janinis J, Patriki M, Vini L et al (2003) The pharmacological treatment of aggressive fibromatosis: a systematic review. Ann Oncol 14:181–190CrossRefPubMedGoogle Scholar
  16. 16.
    Sturt NJH, Gallagher MC, Bassett P et al (2004) Evidence for genetic predisposition to desmoid tumours in familial adenomatous polyposis independent of the germline APC mutation. Gut 53:1832–1836CrossRefPubMedGoogle Scholar
  17. 17.
    Heiskanen I, Jarvinen HJ (1996) Occurrence of desmoid tumours in familial adenomatous polyposis and results of treatment. Int J Colorect Dis 11:157–162CrossRefGoogle Scholar
  18. 18.
    Lefevre JH, Parc Y, Kerneis S et al (2008) Risk factors for development of desmoid tumours in familial adenomatous polyposis. Br J Surg 95:1136–1139CrossRefPubMedGoogle Scholar
  19. 19.
    Nieuwenhuis MH, Dees J, Wijnen J et al (2008) Desmoid tumours in a Dutch cohort of patients with familial adenomatous polyposis. Clin Gastro Hep 6:215–219CrossRefGoogle Scholar
  20. 20.
    Caspari R, Olschwang S, Friedl W et al (1995) Familial adenomatous polyposis: desmoid tumours and lack of ophthalmic lesions (CHRPE) associated with APC mutations beyond codon 1444. Human Mol Genet 4:337–340CrossRefGoogle Scholar
  21. 21.
    Durno C, Monga N, Bapat B et al (2007) Does early colectomy increase desmoid risk in familial adenomatous polyposis? Clin Gastro Hep 5:1190–1194CrossRefGoogle Scholar
  22. 22.
    Friedl W, Caspari R, Sengteller M et al (2001) Can APC mutation analysis contribute to therapeutic decisions in familial adenomatous polyposis? Experience from 680 FAP families. Gut 48:515–521CrossRefPubMedGoogle Scholar
  23. 23.
    Hartley JE, Church JM, Gupta S et al (2004) Significance of incidental desmoids identified during surgery for familial adenomatous polyposis. Dis Colon Rectum 47:334–340CrossRefPubMedGoogle Scholar
  24. 24.
    Bus PJ, Verspaget HW, van Krieken HJM et al (1999) Treatment of mesenteric desmoids with the anti-oestrogenic Toremifene: case histories and an overview of the literature. Eur J Gastroenterol Hepatol 11:1179–1183CrossRefPubMedGoogle Scholar
  25. 25.
    Hansmann A, Adolph C, Vogel T et al (2004) High dose tamoxifen and sulindac as first-line treatment for desmoid tumours. Cancer 100:612–620CrossRefPubMedGoogle Scholar
  26. 26.
    Hartley JE, Church JM, Gupta S et al (2004) Significance of incidental desmoids identified during surgery for familial adenomatous polyposis. Dis Colon Rectum 47:334–340CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • A. Sinha
    • 1
  • P. P. Tekkis
    • 2
  • K. F. Neale
    • 1
  • R. K. S. Phillips
    • 1
  • S. K. Clark
    • 1
    Email author
  1. 1.Polyposis RegistrySt. Mark’s Hospital and Imperial CollegeLondonUK
  2. 2.Royal Marsden Hospital and Imperial CollegeLondonUK

Personalised recommendations